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The role of raised intracranial pressure in the progression and 
refractoriness of migraine. A pilot study.  
 
Abstract 
To assess the prevalence and possible pathogenetic involvement of raised 
intracranial pressure in patients presenting with unresponsive chronic 
migraine (CM), the intracranial opening pressure (OP) and the clinical 
outcome of a single cerebrospinal fluid withdrawal by lumbar puncture (LP) 
has been evaluated in 44 consecutive patients, diagnosed with unresponsive 
CM and evidence of sinus stenosis at magnetic resonance venography. The 
large majority of patients complained of daily or near-daily headache. 
Thirty-eight (86.4%) had an OP >200 mmH2O. Normalization of 
intracranial pressure by LP resulted in prompt remission of chronic pain in 
34/44 patients (77.3%) and an episodic pattern of headache was maintained 
for 2, 3 and 4 months in 24 (54.6%), 20 (45.4%) and 17 (38.6%) patients, 
respectively. The medians of overall headache days/month and of disabling 
headache days/month significantly decreased (p<0.0001) at each follow-up 
versus baseline. Despite the absence of papilledema, 31/44 (70.5%) patients 
fulfilled diagnostic criteria for “Headache attributed to Intracranial 
Hypertension”. Our findings indicate that most patients diagnosed with 
unresponsive CM in specialized headache clinics may present an increased 
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intracranial pressure involved in the progression and refractoriness of pain. 
Moreover, a single LP with cerebrospinal fluid withdrawal results in 
sustained remission of chronic pain in many cases. Prospective controlled 
studies are needed before this procedure can be translated into clinical 
practice.  
 
Clinical relevance summary 
 In episodic migraine patients an usually overlooked comorbid sinus 
stenosis-associated intracranial hypertension without papilledema may 
represent the pathogenetic key, leading to a central sensitization–related 
progression and refractoriness of pain. 
 
 Treatment of the comorbid raised intracranial hypertension, even by a 
single LP with CSF withdrawal, may result in a longstanding restoration of 
the previous episodic pattern of headache attacks. 
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BACKGROUND 
 
Chronic Migraine 
Migraine is a common disorder affecting more than 10% of adult population. 
Its lifetime prevalence in women and men has been reported to be 15% to 
25%, and 6 to 9% respectively [1]. World Health Organisation (WHO) 
reported migraine as one of the world's top 20 most disabling diseases [2] 
and recently, it has been ranked seventh highest among specific causes of 
disability [3]. Migraine which used to be seen as a purely episodic disorder 
is now tended to be accepted as a chronic disorder with episodic 
manifestations. Some migraine sufferers may have attacks of increasing 
frequency over time leading to chronic migraine (CM) which, is termed as 
clinical progression of migraine. CM, a condition with an estimated 
prevalence of about 2%-3% [4-5] is characterized by 15 or more headache 
days per month, 8 of which with migraine features [6]. CM results from the 
progressive worsening of attacks frequency, up to a daily o near daily pain, 
that may develop, more or less progressively, in a part of episodic migraine 
sufferers. The annual rate of progression from episodic to chronic migraine 
is about 2,5% [7-8]. However, recent epidemiological data highlight that CM 
is neither a fixed nor an irreversible condition. In fact, there is an annual rate 
of remission from chronic to episodic pattern of 14% [7]. Thus, migraine 
progression is a dynamic and a reversible event. As a consequence, the 
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identification of the risk factors associated to both, migraine progression and 
remission, is of crucial relevance in headache research and management.  
Risk factors for migraine progression have been extensively studied in 
recent years [8-12]. Besides non modifiable risk factors such as female 
gender, age, low socioeconomic status and  history of head injury, the main 
modifiable risk factors for migraine progression are medication overuse, the 
high frequency of attacks at baseline, obesity, sleep disturbances, psychiatric 
comorbidity and stressful life events. Additionally, idiopathic intracranial 
hypertension without papilledema (IIHWOP), a recently identified [13-17] 
variant of the typical form with papilledema (IIH), is emerging as a new 
potential risk factor for the progression and the refractoriness of migraine 
pain [18-20].  
 
Idiopathic intracranial hypertension  
IIH clinical presentation includes headache, often on a daily basis, 
papilledema, visual disturbances, diplopia, vertigo and tinnitus. According to 
a comparative study, headache features in IIH with or without papilledema 
are very similar but the reported intracranial pressure (ICP) values, in 
IIHWOP, are lower or fluctuating [21], suggesting that papilledema may not 
develop in cases with mild or intermittent ICP increase. With an esteemed 
incidence ranging from 1 to 19/100.000 per year [22-25], IIH is definitely an 
infrequent disease that occurs mostly in women in the childbearing years 
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[23] and has been associated to obesity and to sleep disorders [26-28]. 
Instead, IIHWOP prevalence on general population is not known.  
 
Which is IIHWOP prevalence? 
Generally considered as an infrequent variant of IIH, a quite rare condition, 
in clinical series of chronic/transformed migraine patients IIHWOP is not so 
uncommon, as it can be found in up to 14% of such cases [17, 29-30]. Of 
note, chronic headache is not an obligatory symptom in IIH as it may lack in 
subjects without history of migraine or in presence of a migraine protective 
factor as pregnancy [31]. These observations suggest that IIH clinical 
presentation with chronic headache may require a primary headache 
predisposition and imply that IIHWOP could run almost asymptomatically 
in non primary headache prone individuals. Interestingly, in a large 
community study [32] an asymptomatic increase of ICP has been identified 
in about one half of subjects with bilateral dural sinus stenosis, that 
represented about a quarter (23%) of the population studied, and in none of 
the subject with normal dural sinus anatomy [32]. Actually, an 
asymptomatic form of raised intracranial pressure associated with sinus 
stenosis could be extraordinarily prevalent among healthy individuals.  
According to the above considerations we recently proposed [20] that a 
clinical and epidemiologic continuum might exist among: a) IIH with 
papilledema, possibly representing only the visible part of a hidden and 
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much larger phenomenon; b) symptomatic IIHWOP, presumably largely 
overlooked at present mostly because of frequent CM misdiagnosis, and c) 
asymptomatic IIHWOP a completely hidden condition possibly with high 
prevalence among healthy subjects.  
 
The role of sinus stenosis in IIH pathogenesis 
IIH results from an increased resistance to the CSF outflow into the cerebral 
venous blood collectors, promoted by a raised cerebral venous pressure of 
various aetiologies [33]. Although the pathogenetic role of sinus stenosis is 
debated [34-36], it represents a specific (93%) and sensitive (93%) marker 
of IIH [37], and has been recently included among the radiological signs 
suggestive of IIHWOP [38]. Long considered a consequence of the raised 
ICP without pathogenetic relevance, there is evidence of a significant 
pressure gradient across the stenosis [39]. Moreover, the stenting of sinus 
stenosis is consistently followed by the remission of IIH symptoms [40-42]. 
These findings suggest a causal involvement of sinus stenosis in IIH 
mechanisms.  
We have recently proposed [43] that, in patients with evidence of cerebral 
venous outflow disturbances at magnetic resonance venography (MRV), a 
self-limiting venous collapse (SVC) feedback-loop may lead to a self-
sustained coupled increase of venous blood and CSF pressures up to a 
relatively stable new balance at higher pressure. The SVC mechanism is 
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reversible provided an adequate perturbation is carried at either side of the 
loop, such as sinus stenting on one hand [40-42], and CSF shunting [44-45] 
or even a single lumbar puncture with CSF withdrawal [46-48], on the other. 
The SVC model may explain the longstanding remissions not infrequently 
observed in IIH patients after a single diagnostic LP. 
 
Is IIHWOP a risk factor for migraine progression? 
IIHWOP may present with a mild continuous headache, thus resembling a 
chronic tension-type headache [49]. However, most of the patients show 
superimposed recurrences of severe migraine pain, up to a clinical picture 
indistinguishable from CM [17]. Wang et al. [16] compared the clinical 
features of 25 patients with IIHWOP with those exhibiting chronic daily 
headache (CDH) but with normal CSF pressure and no difference in 
headache profile was found. Besides clinical presentation, IIH and CM also 
share some relevant risk factors such as female gender, obesity and sleep 
disturbances [50-51] and both show a higher prevalence of allodynic 
symptoms [52-55]. Topiramate, a drug with documented efficacy in CM 
[56-57] that shares with acetazolamide the inhibition of carbonic anhydrase 
isoenzyme [58],  has been found as effective as acetazolamide in IIH 
treatment [59], suggesting that the topiramate efficacy in CM could be 
mediated, at least partially, by an acetazolamide-like CSF pressure lowering 
 10
effect. Finally, significant dural sinus stenosis, a marker of IIH, has recently 
been found highly prevalent also in CM [60-62].  
On the basis of the above outlined clinical similarities and considering that, 
on one hand, an asymptomatic sinus stenosis-associated raised intracranial 
pressure may be highly prevalent in general population [32] and, on the 
other, that IIH clinical presentation with chronic headache may require a 
migrainous background [19] we have proposed that a sinus stenosis 
associated IIHWOP, albeit highly prevalent among healthy individuals, in 
migraine predisposed subjects could represent a powerful and modifiable 
risk factor for migraine progression [20]. 
The findings of a recent well conducted study support the above hypothesis. 
In a consecutive series of 98 chronic headache patients, a MRV and LP with 
1 hour ICP monitoring were performed [60]. Sinus stenosis was present in 
48.9% of the sample. Based on 1 hour ICP monitoring, an overall IIHWOP 
prevalence of 44,8% was found. This group represented the 91.6% of sinus 
stenosis carriers. Conversely, CSF pressure resulted within normal limits in 
all chronic headache patients showing a normal MRV. Intriguingly, the 
Authors noticed that a transitory (2-4 weeks) improvement of headache after 
the LP was reported by the majority of patients with raised ICP. These 
observations confirm the high prevalence of IIHWOP in chronic headache 
sufferers and its strict association with sinus stenosis. However, the lack of 
venous outflow disturbances and of raised ICP in more than half of patients 
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with chronic headache [60] and the high prevalence of sinus stenosis-
associated raised ICP found in subjects without chronic headache [32] 
indicate that IIHWOP is neither a necessary nor a sufficient condition for 
chronic headache development but has to be considered a risk factor for 
progression and refractoriness of pain in primary headache prone 
individuals. 
 
 
AIM OF THE STUDY 
 
Intracranial hypertension and progression of migraine 
Although reported, the rate of responders and the duration of the clinical 
benefit after a single CSF withdrawal by LP in IIH/IIHWOP patients is 
unknown. To assess the intracranial pressure in unresponsive CM sufferers 
and to test the possible involvement of IIHWOP in the progression and 
refractoriness of migraine, we performed a clinical prospective study in 
which the opening pressure (OP) and the clinical outcome of a single CSF 
withdrawal by LP have been evaluated in a series of consecutive CM/TM 
patients, carefully selected for unresponsiveness to medical treatments and 
with evidence of cerebral venous outflow disturbances at MRV. 
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PATIENTS AND METHODS 
 
Study population 
The study sample consisted of consecutive CM outpatients enrolled at 
Headache Centre of  Department of Neurosciences of University of Naples 
"Federico II", who agreed to undergo CSF withdrawal via LP and who 
fulfilled the following criteria: 
 
Inclusion criteria 
  (i) diagnosis of transformed migraine (TM) with or without 
medication overuse according  to the Chronic Daily Headache criteria 
established by Silberstein and Lipton [63] up to 2006, and subsequently a 
diagnosis of chronic migraine (CM) according to the ICHD-II R2 criteria 
[64];  
  (ii) directly assessed unresponsiveness (failure to return to an episodic 
pattern of attacks) to withdrawal of medication overuse (when applicable) 
and to at least 2 consecutive migraine  preventive treatments at 
standard doses lasting at least 2 months each. Drugs were chosen on  the 
basis of the patient’s co-morbidity profile among 7 drugs effective in 
migraine prevention (namely, amytriptiline, propranolol, flunarizine, 
pizotifen, valproic acid, zonisamide and topiramate); 
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 (iii) normal brain magnetic resonance imaging, and availability of a 
brain MRV; 
 (iv) cerebral venous outflow disturbances defined as bilateral 
transverse sinus (TS) stenosis/hypoplasia or at least unilateral segmental TS 
flow gap/aplasia at uncontrasted MRV; 
 (v) availability of complete headache diary-based clinical data starting 
at least 1 month before LP (baseline) to at least 4 months after LP, or 
collection of possible missing headache diary data by direct visit or phone 
interview.  
 
Exclusion criteria:  
 (i) evidence of a secondary cause of intracranial hypertension, 
including venography evidence of cerebral venous thrombosis and abnormal 
CSF chemistry and/or cell counts; 
 (ii) presence of papilledema;  
 (iii) age < 18 years. 
 
Study protocol 
Outpatients fulfilling the above-mentioned criteria were admitted to hospital. 
They underwent a complete neurological and physical examination 
including height and weight measurements. The absence of papilledema was 
confirmed by an ophthalmologic consultation with funduscopic examination. 
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According to institutional policy, patients underwent brain magnetic 
resonance and MRV in external radiologic services linked to the public 
health system. Consequently, there was a lack of homogeneity in the MRV 
techniques used. All MRVs were re-evaluated by an expert neuroradiologist. 
Some patients had spontaneously interrupted prophylactic treatment at least 
1 month before LP. To avoid confounders of clinical outcome, all patients 
were asked to maintain their the current regimen up to 4 months after LP. 
Headache diary data referring to 30 days before LP were collected at 
admission and served as baseline. All patients were recommended to 
continue recording all headache activity also during the 4 months after LP.  
Cerebral spinal fluid pressure was measured with a standard spinal 
manometer calibrated in mm Hg (“Lumbal” Riester, Germany) connected to 
the spinal needle via a three-way stopcock, with the patient in the lateral 
recumbent position with legs extended. All pressure values were multiplied 
by 13.56 (i.e., the specific weight of mercury) to convert values into 
mmH20. The spinal needle was inserted with the bevel orientation parallel to 
the long axis of the spine, the stilet was reinserted before the needle was 
extracted, and the patient was invited to rest in bed for at least two hours 
after LP. In patients with an OP ≤ 200 mmH20 the procedure was stopped 
after withdrawal of 6 mL of CSF required for routine analysis. In subjects 
with an OP >200 mmH2O, ICP was measured after each withdrawal of 2 
mL CSF, up to its normalization (at about 100 mmH2O) or up to the 
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withdrawal of about 30 mL of CSF.  We used a 20 G spinal needle because 
the rate of spontaneous CSF drip with thinner needles (22 G or smaller) is 
very low (up to less than 1 mL/min) when the patient is in a recumbent 
position, and it may take more than 1 minute to allow the correct 
transduction of CSF pressure onto a standard spinal manometer [65]. This 
would have prolonged unacceptably the CSF withdrawal procedure, and 
consequently increased the patient’s discomfort and the risk of infectious 
complications. Lumbar punctures were performed by 2 operators  using the 
same technique and instruments.  
The upper limit of normal ICP is debated [32,38, 66-70]. We used the value 
of 200 mmH2O because IIHWOP patients may have lower ICP values than 
IIH patients [21]. Moreover, in a large sample of individuals without signs 
or symptoms of raised ICP [32], OP values above 200 mmH2O were closely 
associated with sinus stenosis.  
All patients signed an informed consent declaration before enrollment in the 
study. The study was approved by the local Ethics Committee. 
 
Clinical evaluation and data collection 
All the patients’ clinical data were collected using the AIDA Cefalee, a 
validated software [71] for headache management based on ICHD-II criteria 
[66]. All patients were prospectively evaluated for headache frequency and 
intensity in two structured follow-up visits scheduled 2 and 4 months after 
 16
LP. At the first visit, data were collected regarding months 1 and 2 after LP, 
and at the second visit data were collected regarding months 3 and 4 after 
LP. A few patients who missed the follow-up visits were given a new 
appointment or communicated their headache diary data by telephone. 
Therefore, complete data were obtained for all the patients. The median 
number of overall headache days (of any intensity) and of disabling 
headache days (i.e. with moderate or severe pain) in the 30 days before LP 
served as baseline data and were compared with the corresponding medians 
calculated at each follow-up. Clinical data collected one month after LP are 
reported but are not included in the statistical evaluation because of the 
confounding effect of post-LP headache (PLPH), which is highly prevalent 
in chronic headache sufferers [72-73]. Subsequent follow-ups were planned 
on clinical basis. Data on responder rate after LP , subsequent to 4th month 
follow-up, and the outcome after LP repetition, performed in some of our 
patients, are briefly reported. 
 
Control groups 
We compared the OP values of our series (Group A) with those of 2 control 
groups: Group B, which derives from a previous study of 217 neurologic 
patients without chronic headache or other symptoms or signs of raised 
intracranial pressure [32], and Group C, which is a retrospective series of 13 
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patients diagnosed at our clinic affected by IIH with papilledema in which 
OP was measured with the same LP procedure used for Group A. 
 
End points 
The primary end points of the study were:  
 (i) the prevalence of OP >200 mmH2O; 
 (ii) the percentage of “responders” (i.e. return to fewer than 15 
headache days per month) during the 2nd, 3rd and 4th month after CSF 
withdrawal by LP;  
 (iii) the reduction of the median values of overall headache days per 
month and of disabling headache days per month during the 2nd, 3rd and 4th 
month after LP versus baseline.  
The secondary endpoints were:  
 (i) difference in the baseline and primary endpoints between the 
 subgroup undergoing  preventive treatment at the time of LP and 
 the subgroup not undergoing preventive  treatment;  
 (ii) existence of factors predictive of a long-term response (a return to 
 an episodic pattern of attacks during the 2nd month after LP), 
 namely, body mass index (BMI),  OP, CSF volume withdrawn or 
 ongoing prophylactic treatment;   
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 (iii) comparison of OP distribution in our series (Group A) versus 
 Group B (no signs or symptoms of IIH) and Group C (definite IIH 
 with papilledema). 
 
Statistical analysis  
Normality of data distribution was determined with the Anderson-Darling 
test. When normality was not assumed, non-parametric tests were used to 
assess differences in medians, namely, the Mann-Whitney-Wilcoxon and 
Friedman's tests for repeated measures with post-hoc test. Otherwise 
equality of variances was tested by the Fisher-Snedecor F-test using Sidak's 
correction for multiple comparisons. Differences in means were tested with 
Student's t-test (with Satterthwaite's correction when variances differed) with 
Sidak's correction for multiple comparisons. Values of p < 0.05 were 
considered statistically significant. A bias-reduced logistic regression model 
was performed to determine if some of the parameters measured at the time 
of LP (BMI, OP, amount of CSF withdrawn and presence/absence of 
ongoing preventive treatment) could be predictors of a long-term response 
(defined as a return to an episodic pattern of migraine attacks 2 months after 
LP). A statistics software freely available on the web was used for the 
logistic regression analysis [74].  
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RESULTS 
 
Population description 
Of the 278 consecutive patients diagnosed with TM/CM who completed the 
diagnostic and therapeutic workup, 56/278 (20.1%) were labeled 
“unresponsive” after failure of analgesic withdrawal (if applicable) or of at 
least two different preventive treatments lasting at least 2 months each. All 
patients had suffered from episodic migraine that had worsened up to an 
almost continuous daily migraine pain of variable intensity. Bilateral dural 
sinus narrowing, unilateral flow gap or aplasia at MRV were present in 
52/56 (92.8 %) of unresponsive patients. Of the 52 subjects with cerebral 
venous outflow abnormalities, 44 (84.6%) agreed to LP and constitute our 
study sample.  
The demographic features of our patients are listed in Table 1. Twenty-
six of the 44 patients (59.1%) were found to overuse symptomatic 
medication defined according to ICHD-II [66] at first observation but failed 
to respond to analgesic withdrawal. Seven were found to overuse 
symptomatic mediation also at the time of LP. Twelve patients (27.3%) had 
spontaneously interrupted treatment at least one month before LP because of 
inefficacy and/or reduced tolerance. In the remaining 32 patients (72.7%) 
with ongoing therapy, the actual exposure to the last treatment was 12.2 
weeks (range 8.3-23.8). Physical and neurological examinations were 
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unremarkable in all patients. No patient complained of diplopia or showed 
papilledema. 
Time-of-flight MRV was used in 17 patients (38.6%) and three-
dimensional phase contrast MRV in the remaining 27 (61.4%) patients. The 
main sinus stenosis patterns found at MRV in our series are illustrated in 
Figure 1. Bilateral TS stenosis/flow-gaps were identified in 15/44 cases 
(34.1%). An isolated unilateral TS gap was identified in 17/44 (38.6%) 
patients; a combined unilateral TS stenosis associated with a gap at the 
posterior segment of the superior sagittal sinus was observed in 2/44 patients 
(4.5%), and a unilateral TS stenosis/flow gap associated with the separation 
of superficial and deep venous circulation at torcular level was found in the 
remaining 10/44 (22.7%) cases.  
 
Baseline 
During the 30 days before LP, most patients had daily or near-daily pain. 
The median of overall headache days per month was 29.5 (95% C.I. 27-30; 
range 20-30); the median of disabling headache days per month was 12 
(95% C.I. 9-17; range 5-25). 
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 Opening pressure 
The median OP was 244 mmH2O (95% C.I. 224-265; range: 81-403). An 
OP >200 mmH2O was found in 38/44 patients (86.4%) of whom 19 (43.2%) 
had an OP >250 mmH2O. The distribution of OP is reported in Figure 2.  
 
Outcome one month after lumbar puncture 
Within a few hours to 3 days after LP, 30 (68.2%) patients developed an 
orthostatic headache that fulfilled the ICHD-II criteria for PLPH [66]. 
Median PLPH duration was 7.5 days (range 1-30). PLPH was treated 
conservatively in all patients (hydration, non-steroidal anti-inflammatory 
drugs and bed rest). Headache diary data of the 1st month after LP could not 
be unequivocally attributed to previous pain or to PLPH, and therefore were 
not included in the statistical analysis. However, of the 14 patients without 
PLPH, 11 (78.5%) experienced a sudden decrease of pain soon after LP or, 
in some cases even during LP. Twenty-three of 30 (76.6%) patients with 
PLPH reported the disappearance of daily pain soon after PLPH resolution 
or in the late PLPH stage, provided a recumbent position was maintained. 
Overall, 34/44 (77.3%) patients experienced a dramatic decrease of pain at 
least for a few days or weeks after LP or at PLPH resolution. Based on this 
finding, 31 of these cases (70.4% of the whole sample) fulfilled the ICHD-II 
criteria for “Headache attributed to IIH” [66] despite the absence of 
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papilledema. The criteria were not fulfilled in 2 patients with OP <200 
mmH2O or in 1 obese patient with OP <250 mmH2O. 
 
Primary end-points 
The primary endpoint results are summarized in Table 2. Twenty-four 
subjects (54.6%) experienced a return to an episodic pattern of headache 
during the 2nd month after LP; this was maintained in 20 patients (45.4%) at 
the 3rd month, and in 17 (38.6%) at the 4th month after LP. Two of 6 
patients with an OP <200 mmH2O were classified as “responders” 2 months 
after LP. One of them still had episodic headache 4 months after LP. The 
median overall headache days per month decreased significantly (p<0.0001) 
from 29.5 days at baseline to 12 in the 2nd month, 19 days in the 3rd month 
and 26 days in the 4th month. No differences were found between the data 
obtained 2, 3 and 4 months after LP. The median number of disabling 
headache days per month decreased significantly (p<0.0001) from 12 at 
baseline to 5.5 in the 2nd month, 5 in the 3rd month and 6.5 in the 4th 
month. There were no differences between the data obtained at the 2nd and 
3rd months after LP, whereas the number of disabling headache days per 
month was significantly higher at the 4th month than at the 2nd and 3rd 
months. 
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Secondary end points  
We evaluated differences between patients with (n=32; 72.7%) and without 
(n=12; 27.3%) prophylactic therapy at the time of LP. At baseline, the 
median of disabling headache days, but not the overall number of headache 
days, was significantly lower in patients with ongoing treatment versus 
patients without [9.5; 95% C.I: 7-15 vs. 16.0; 95% C.I. 8-20 (p=0.02)]. The 
two groups did not differ significantly in terms of median OP or in the rate 
of responders at each follow-up. Neither did they differ in terms of the 
medians of overall headache days per month and of disabling headache days 
per month at each follow-up. The bias-reduced logistic regression model 
showed that none of the parameters measured at the time of LP (BMI, OP, 
amount of CSF withdrawn and presence/absence of ongoing preventive 
treatment) independently contributed to the long-term response (OR= 1.23, 
95% CI 0.14-11.09; OR= 1.01, 95% CI 0.14-7.24; OR= 0.92, 95% CI 0.12-
7.37; OR= 1.85, 95% CI 0.03-114.21, respectively for BMI, OP, mL of CSF 
withdrawn, presence/absence of ongoing preventive treatment). 
Table 3 shows OP distribution of our series (Group A), and of the two 
control groups (Group B  without signs and symptoms of raised ICP; Group 
C with definite IIH with papilledema). The OP distributions in the three 
groups were Gaussian. Analysis of variance showed that the variance of 
Group B differed from the variances of the two groups with raised ICP 
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(Group A and Group C), but the variances of the latter two were equal. 
Finally, the means of OP differed among the three groups. 
 
Additional follow-up data  
Of the 17 patients still suffering from episodic headache 4 months after LP, 
13 (29.5%) and 9 (20.5 %) remained “episodic” 6 and 12 months, 
respectively after LP. Seven patients (15.9%) still had an episodic pattern of 
migraine attacks after a median observation period of 25 months (range 12-
60 months).  
 
Repetition of the lumbar puncture 
Cerebral spinal fluid withdrawal via LP was carried out 16 times in 13 
patients: 9 classified as responders at the 2nd month who relapsed and 4 non 
responders who had a clear-cut but short-lasting remission of CM after LP. 
An OP > 200 mmH2O was found in all procedures but 3. An extended 
benefit was observed in 7 cases (all belonging to the responder group after 
the first LP).  
Relapses after LP were usually reported as abrupt in onset and were 
announced by the reappearance of a mild to moderate continuous pain at 
awakening associated with concomitant increase of disabling headache days 
frequency. LP with CSF subtraction were repeated in 13 patients: 9 
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responders at 2nd month who relapsed overtime and 4 non responders at 2nd 
month who had shown a clear-cut but short-lasting remission of CM after 
the first LP.  
After the second LP we observed no change of the ongoing pain in 2 cases 
(1 responder and 1 non responder after the first LP), a short-lasting (1 to 2 
weeks) benefit in 4 (1 responder and 3 non responder after the first LP) and 
the replication of an extended benefit in 7 cases (all responders after the first 
LP). Of these, 5 patients relapsed again after a median interval of 5 months 
(range 1,5-12) whereas 2 were still episodic after a follow-up of 2 and 42 
month respectively.  
LP has been repeated a third time in 3 cases. Two patients who relapsed 7 
and 12 months after the 2nd LP replicated an extended benefit after the 3rd 
LP and were still episodic at the end of the study. (after 2 and 3 months 
respectively). An additional patient, classified as responder after the 1st LP 
but showing an early relapse after the second LP, unsuccessfully underwent 
the 3rd LP.  
The median OP of the 16 repeated LP was 222.5 mmH2O (95% C.I. 213-
244; range 135-325). An  OP > 200 mmH2O was found in all procedures but 
3. 
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DISCUSSION 
 
In our series of selected unresponsive CM/TM patients, pain mostly 
occurred on a daily or almost daily basis. The prevalence of sinus venous 
stenosis was even higher (52/56; 92.8%) than reported in unselected chronic 
headache patients [60,62] and close to the prevalence found in IIH patients  
(93.0%) [37]. The vast majority of our patients (38/44; 86.4%) had an OP 
>200 mmH20, and a mean OP  significantly higher than asymptomatic 
patients (Group B) but, as expected [21], significantly lower than patients 
with a definite diagnosis of IIH (Group C). Based on ICHD-2 criteria [66], 
70.4% of our patients could be diagnosed with “Headache attributed to IIH” 
despite the absence of papilledema. These findings indicate that proven 
unresponsiveness to medical treatment strongly predicts the presence of 
sinus stenosis and of a raised ICP in clinical series of chronic migraine 
patients.  
Normalization of ICP consequent to a single CSF withdrawal by LP was 
followed by the return to an episodic pattern of headache that lasted at least 
2 months in more than half the patients (24/44; 54.6%), and at least 4 
months in more than one-third of patients (17/44; 38.6%). Both overall and 
disabling headache days per month were significantly fewer at each follow-
up visit compared with baseline values. The benefit persisted even longer in 
7 patients (15.9%), i.e., after a median follow-up of 25 months (range 12-60 
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months). Overall, 77.3% of patients experienced a clear cut amelioration of 
pain soon after LP or at PLPH remission, which was maintained in 54.6% of 
them at the 2nd month. Finally, most responders at the first LP who 
relapsed, responded also to a subsequent LP. These findings strongly support 
the existence of a causal link between CSF withdrawal via LP and clinical 
outcome. 
Two of the 6 patients with a normal OP also responded to the withdrawal of 
6 mL CSF, which was required for routine analysis. It is conceivable that 
these patients were affected by intermittent IIHWOP [60, 75-76], but ICP 
monitoring, which is required to identify such cases, was not performed in 
this study.  
The clinical outcome measures of this study did not differ between 
subgroups with and without ongoing treatment during follow-up. As 
expected, only the number of disabling headache days at baseline was 
significantly lower in patients with ongoing medical treatment. Therefore, 
ongoing preventive treatment did not seem to affect the clinical outcome of 
our patients. Similarly, baseline BMI, OP and the amount of CSF withdrawn 
did not seem to predict the long-term benefit of the procedure.  
In our sample, 30/44 (68.2%) patients developed a post lumbar puncture 
headache (PLPH) after the first therapeutic lumbar puncture (LP). Although 
extraordinarily elevated, this finding is in agreement with previous 
observations in chronic headache sufferers undergoing even a diagnostic LP 
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(i.e. with only a few ml of CSF collection) [72-73; 77-78]. Using 22 G 
needles, a 85,7% prevalence of PLPH has been recently reported in the 
subgroup with chronic headache of a prospective series of neurologic 
patients undergoing diagnostic LP (cases requiring LP for therapeutic CSF 
drainage were excluded from the series) [78].  Conversely, using 20 G 
needles to perform diagnostic LP in a large unselected neurologic patients 
series, a previous history of chronic headache was found in 50 out of the 88 
cases (56,7%) who developed PLPH [73]. While the reasons for such an 
high prevalence of PLPH in chronic headache sufferers remains to be 
clarified, the above considerations suggest that neither the use of 20 G 
needles nor the subtraction of large amounts of CSF played a relevant role in 
high PLPH prevalence observed in this series. 
The most striking finding of our study is that the large majority of patients 
diagnosed with proven unresponsive CM in specialized centers might be 
suffering from chronic headache secondary to IIHWOP. This implies that 
IIHWOP mimicking CM is: a) a condition much more prevalent than 
hitherto believed; b) commonly misdiagnosed as CM if the diagnosis is 
based on ICHD-2R criteria; and c) strictly predicted by refractoriness to 
preventive treatments. Moreover, we show that normalization of ICP by LP 
may be effective in patients with a long history of refractory chronic 
headache, who represent about one-fifth of the patients screened in this 
study. 
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All our patients had a history of episodic migraine that had worsened over 
time. A raised ICP associated to sinus stenosis was reported to occur almost 
asymptomatically in up to 11% of individuals of a community series, which 
indicates that it is not a sufficient cause of chronic headache [32]. 
Conversely,  in unselected CM patients, about half the cases were not 
associated with significant sinus stenosis nor with a raised ICP, which 
indicates that a raised ICP is not necessary for chronic headache 
development [60]. Moreover, there is evidence that chronic headache 
presentation of IIH may require a migrainous background [31].  
According to the SVC model [43], in subjects harbouring one ore more 
collapsible segments of central veins, any promoting factor leading to a 
sufficient increase of either CSF pressure or cerebral venous pressure, could 
trigger a positive feedback loop between the CSF pressure, that compresses 
the sinus, and the consequent venous pressure rise, that increases the CSF 
pressure. The cerebral venous congestion induced by the recumbent position 
may aggravate a running migraine pain [79-80]. We speculate that the 
opposite increased pressures acting on both, the blood and the CSF side of 
the venous wall, might promote the activation of dural sinus 
trigeminovascular nociceptors, leading to central sensitization of pain 
pathways [43]. Allodynia, a clinical marker of central sensitization, usually 
develops in the course of primary headache attacks [81-83] but is bilaterally 
detected during the intercritical phase in over 70% of chronic headache 
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subjects [54]. Among migraine sufferers, allodynia has been associated with 
female sex, frequent headache, increased BMI and depression [84-85]. It 
may represent the final pathway on which converge the actions of most risk 
factors for migraine progression validated by the recent literature [86]. 
Interestingly, Ekizoglu et al. [55] recently found allodynia in about one half 
of a IIH patients series and it was associated with a chronic migraine-like 
headache profile.  
On the basis of the above considerations and findings we recently proposed 
[20] that the mechanism linking raised ICP to migraine pain progression 
may rely on the central sensitization of pain pathways, induced by a 
continuous trigeminovascular firing at the congested sinus stenosis level. 
This series of considerations support the alternative hypothesis that a 
frequently overlooked comorbid sinus stenosis-associated increased ICP, 
although very common in otherwise healthy subjects, is, in migraine-prone 
individuals, a powerful modifiable risk factor for pain progression, and is 
causatively involved in its refractoriness [19]. A prospective controlled 
study is needed before withdrawal of CSF by LP could be translated into 
routine clinical practice. Studies are also required to determine if patients 
with chronic pain and raised ICP should be diagnosed with IIHWOP 
mimicking CM or if they should be considered primary migraine subjects 
with a comorbid IIHWOP-dependent progression and unresponsiveness of 
pain. Whatever the case, our findings suggest that intracranial hypertension 
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without papilledema should be considered in all patients referring to 
specialized headache clinics for an almost daily migrainous pain 
unresponsive to medical treatments and with evidence of dural sinus 
abnormalities at MRV.  
 
Study limits  
The main limitation of this study is the lack of a control group for the 
clinical outcome of LP. However, even given the susceptibility of migraine 
patients to the placebo effect, the lack of a control group may be partially 
counteracted by the very high prevalence of intracranial hypertension in our 
series (86.4%), the immediate improvement observed after LP (or soon after 
PLPH resolution) in patients selected for longstanding and refractory chronic 
headache syndromes and, lastly, the reproducibility of the sustained benefit 
at LP repetitions in 7 out of 9 responders after relapse.  
At time of LP a significant proportion of patients (19/44, 43.2%) were 
treated with topiramate (100 to 200 mg per day), a drug that can lower ICP 
[59]. However, this potential bias would have only resulted in an 
underestimation of OP values, without affecting the strength of data. The 
inhomogeneity of the MRV technique is an unavoidable consequence of the 
naturalistic scenario of this study. However, it precludes the possibility of 
establishing a reliable statistical correlation between the degree of stenosis 
and the baseline data or clinical outcome. Studies designed to establish a 
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more precise definition of this radiologic finding and to identify the most 
suitable MRV technique to use in IIH patients are urgently needed.  
 
 
CONCLUSIONS  
 
IIHWOP shares with CM a number of clinical features and it can be 
documented in chronic headache series much more frequently than expected 
[17, 29-30]. However, the lack of venous outflow disturbances and of raised 
ICP in more than half of patients with chronic headache [60], on one hand, 
and the high prevalence of sinus stenosis-associated raised ICP found in 
subjects without chronic headache [32] on the other, indicate that IIHWOP 
is neither a necessary nor a sufficient condition for chronic headache 
development but has to be considered a powerful and modifiable risk factor 
for chronification of migraine.   
Our findings show that the vast majority of patients diagnosed with 
unresponsive CM in specialized headache clinics may present increased 
intracranial pressure that is involved in the progression and refractoriness of 
pain. A single CSF withdrawal via LP may result in a sustained remission of 
chronic pain in a relevant proportion of cases. We speculate that a central 
sensitization induced by a continuous trigeminovascular firing at the 
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congested sinus stenosis level may be the mechanism linking the raised ICP 
and migraine pain progression in such patients. 
Prospective controlled studies are needed before this procedure can be 
translated into routine clinical practice. Nonetheless, we suggest that 
intracranial hypertension without papilledema should be considered in all 
patients suffering from an almost daily migrainous pain with evidence of 
unresponsiveness to medical treatments and cerebral venous outflow 
abnormalities at MRV. 
 34
TABLES AND FIGURES 
 
 
 
Table  1.  Demographic and clinical data 
 
 
Subjects, No. (%) 44 (100%) 
Women, No. (%) 39 (88.63%) 
Men, No. (%) 5 (11.36%) 
Age, median value (95% CI)  37,5 (33-40) 
BMI, median value (95% CI) 26,17 (24,46-28,69) 
 - Normal weight (BMI 20-25), No. (%) 19 (43,2%) 
 - Overweight (BMI 25-30), No. (%) 14 (31,8%) 
 - Obese (BMI>30), No. (%) 11 (25,0%) 
Medication overuse at first observation, No. (%) 26 (59,1%) 
Medication overuse at time of LP, No. (%) 7 (15,9%) 
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Table 2.  Clinical outcome after CSF withdrawal 
 
 
 
Baseline 
 
Follow-up 1 
 
Follow-up 2 
 
   2
nd month 3rd month  4th month 
Responders 
(episodic headache pattern) 
 n. (%)                  
- 
24 
 (54.5%)  
20  
(45.4%)   
17 
(38.6%)   
Overall headache 
days/month  
Median (95% C.I.; range) 
29.5 
 (27-30; 20-30)
 
12  a, b 
(6-28; 2-30) 
  
 
19  a, b 
 (6-29; 1-30) 
 
 
26  a, b 
 (7-28; 3-30)
 
Disabling headaches 
days/month 
Median (95% C.I.; range) 
12  
(9-17; 5-25) 
 
5.5  a 
 (4-8; 0-25) 
  
 
5  a 
 (3-11; 0-23) 
  
 
6.5  a,c 
(5-12; 1-25) 
 
        
a p<0.0001 compared to baseline 
b not significant compared with the other time point follow-up values 
c p<0.01 compared to the 2nd and 3rd month follow-up 
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Table 3 Comparison of opening pressure distribution in study series vs. 
control groups 
 
 
 
 
Group A 
 
Study series 
Group B* 
Patients without signs or 
symptoms of IIH 
Group C 
Patients with definite IIH 
p 
Patients n. 44  217 13  
 
OP, mmH2O 
mean (S.D.) 
245.5 (62.8)  149.3 (47.5) 310.4 (76.7)  a,b,c 
 
*  data derived from Reference 32.   
 
a Anderson-Darling test for normality distribution: p > 0.05 for each group  
 (data normally distributed) 
 
b Fisher F-test for equality of variances:   - Group A vs. Group B:  p = 0.01 
                                                                  - Group A vs. Group C:  p = 0.32   (n.s) 
                                                                  - Group B vs. Group C:  p = 0.005  
                                                                 
c Student t-test for equality of means:      - Group A vs. Group B:   p < 0.01 
                                                                  - Group A vs. Group C:   p < 0.01  
                                                                  - Group B vs. Group C:   p < 0.01  
_____________________________________________________________________________________________ 
 
OP, opening pressure; IIH, idiopathic intracranial hypertension 
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Fig. 1 Examples of the main sinus stenosis patterns found at MRV. (A) 
Bilateral TS stenosis; (B) Isolated unilateral TS stenosis; (C) Unilateral TS 
stenosis associated with posterior SSS stenosis; (D) Unilateral TS stenosis 
combined with separation of superficial and deep venous system at torcular 
level.  
MRV: Magnetic Resonance Venography; TS: Transverse sinus; SSS: 
Superior sagittal sinus. 
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Fig. 2 Distribution of the opening pressure in the whole sample. 
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